Ranibizumab

(Lucentis®)

Lucentis®

Drug updated on 4/17/2024

Dosage FormInjection (intravitreal; 10 mg/ml [0.5 mg], 6mg/ml [0.3 mg])
Drug ClassVascular endothelial growth factor inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for treatment of neovascular (wet) age-related macular degeneration (AMD).
  • Indicated for treatment of macular edema following retinal vein occlusion (RVO).
  • Indicated for treatment of diabetic macular edema (DME).
  • Indicated for treatment of diabetic retinopathy (DR).
  • Indicated for treatment of myopic choroidal neovascularization (mCNV).

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated, with no liability accepted for reliance on it. Learn more.

  • Ranibizumab (Lucentis) is indicated for the treatment of various eye conditions including neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.
  • Forty-six systematic reviews/meta-analyses were reviewed to gather information about the drug's effectiveness and safety compared with other treatments.
  • The data suggests that Lucentis may be compared against other anti-VEGF therapies such as aflibercept, brolucizumab, or off-label bevacizumab. Key parameters for comparison include improvement in visual acuity, reduction in retinal thickness, and fewer injections required, which can infer a better safety profile.
  • Adverse events related to Ranibizumab (Lucentis) are documented. These include risks like endophthalmitis, intraocular inflammation, or elevation in intraocular pressure among others.
  • Some studies focus on specific populations such as diabetics or elderly patients who might show varying responses to the treatment. This could provide valuable insights into subgroup considerations.
  • Methodological quality assessment was performed by looking at risk bias within these studies along with precision estimates and consistency across different research, providing evidence certainty regarding its use for treating aforementioned eye conditions.
  • Real-world efficacy versus controlled clinical trial settings has been highlighted, where some studies compare how Lucentis performs under broader clinical practice conditions rather than just controlled environments.
  • The limitations noted from current literature include a lack of long-term data availability on certain subtypes of diseases treated by Lucentis, along with inconsistencies in reported outcomes, making it crucial to consider these factors.

Product Monograph / Prescribing Information

Document TitleYearSource
Lucentis (ranibizumab) Prescribing Information.2024Genentech Inc., San Francisco, CA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Anti-vascular endothelial growth factor therapy and retinal non-perfusion in diabetic retinopathy: a meta-analysis of randomised trials.2024Acta Ophthalmologica
Efficacy and safety of brolucizumab, aflibercept, and ranibizumab for the treatment of patients with visual impairment due to diabetic macular oedema: a systematic review and network meta-analysis.2023Diabetes Therapy
Efficacy and safety of anti-vascular endothelial growth agents for the treatment of polypoidal choroidal vasculopathy: a systematic review and meta-analysis.2023Survey of Ophthalmology
Comparative efficacy of aflibercept and ranibizumab in the treatment of age-related macular degeneration with retinal pigment epithelial detachment: a systematic review and network meta-analysis.2023BMC Ophthalmology
Baseline diabetic retinopathy severity and time to diabetic macular edema resolution with ranibizumab treatment: a meta-analysis.2023Ophthalmology Retina
Efficacy and safety of brolucizumab, aflibercept, and ranibizumab for the treatment of patients with visual impairment due to diabetic macular oedema: a systematic review and network meta-analysis.2023Diabetes Therapy
Comparison of antivascular endothelial growth factor treatment for myopia choroidal neovascularisation: a systematic review and meta-analysis of randomised controlled trials.2023BMJ Open
Efficacy of as-needed intravitreal injection compared to 3-monthly loading of anti-vascular endothelial growth factor agents for branch retinal vein occlusion.2023Scientific Reports
Efficacy of ranibizumab combined with photocoagulation for diabetic retinopathy: a meta-analysis study.2023Medicine
Ranibizumab for the treatment of retinopathy of prematurity: systematic review and meta-analysis.2023Frontiers in Pediatrics
Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.2023Cochrane Database of Systematic Reviews
The management of neovascular age-related macular degeneration: a systematic literature review of patient-reported outcomes, patient mental health and caregiver burden.2023Acta Ophthalmologica
Effect of ranibizumab on retinopathy of prematurity: a meta-analysis.2022Frontiers in Pharmacology
A network meta-analysis of retreatment rates following bevacizumab, ranibizumab, aflibercept, and laser for retinopathy of prematurity.2022American Academy of Ophthalmology
Outcomes of over 40,000 eyes treated for diabetic macula edema in routine clinical practice: a systematic review and meta-analysis.2022Advanced Therapeutics
Long-term outcomes for patients treated for macular oedema secondary to retinal vein occlusion: a systematic review.2022BMJ Open Ophthalmology
Comparative efficacy of brolucizumab in the treatment of neovascular age-related macular degeneration: a systematic literature review and network meta-analysis.2022Advanced Therapeutics
Real-world evidence in the management of diabetic macular edema with intravitreal anti-VEGFs in Asia: a systematic literature review.2022Clinical Ophthalmology
Efficacy and safety of antivascular endothelial growth factor (anti-VEGF) in treating neovascular age-related macular degeneration (AMD): a systematic review and meta-analysis.2022Journal of Immunology Research
Effect of anti-VEGF therapy on the disease progression of neovascular age-related macular degeneration: a systematic review and model-based meta-analysis.2022Journal of Clinical Pharmacology
Comparison of efficacy and safety between conbercept and ranibizumab in neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials.2022Ophthalmic Research
Managing neovascular age-related macular degeneration in clinical practice: systematic review, meta-analysis, and meta-regression.2022Journal of Clinical Medicine
The 12- and 24-month effects of intravitreal ranibizumab, aflibercept, and bevacizumab on intraocular pressure a network meta-analysis.2021American Academy of Ophthalmology
Comparative efficacy and safety of different regimens of ranibizumab for neovascular age-related macular degeneration: a network meta-analysis of randomised controlled trials.2021BMJ Open
Intravitreal ranibizumab versus dexamethasone implant in macular edema due to branch retinal vein occlusion: systematic review and meta-analysis.2021European Journal of Ophthalmology
Disease stability and extended dosing under anti-VEGF treatment of exudative age-related macular degeneration (AMD) - A meta-analysis.2021Graefe’s Archive for Clinical and Experimental Ophthalmology
Anti-vascular endothelial growth factor therapy for age-related macular degeneration: a systematic review and network meta-analysis.2021Systematic Reviews
Ranibizumab and conbercept for treating wet age-related macular degeneration in China: a systematic review and meta-analysis.2021Medicine Open
Efficacy and safety of various treatments for proliferative diabetic retinopathy: a systematic review and network meta-analysis.2021Frontiers in Pharmacology
Managing diabetic macular edema in clinical practice: systematic review and meta-analysis of current strategies and treatment options.2021Clinical Ophthalmology
A systematic review and meta-analysis to compare the efficacy of conbercept with ranibizumab in patients with macular edema secondary to retinal vein occlusion.2020Medicine
Intravitreal ranibizumab versus dexamethasone implant in macular edema due to branch retinal vein occlusion: systematic review and meta-analysis.2020European Journal of Ophthalmology
Comparative safety of bevacizumab, ranibizumab, and aflibercept for treatment of neovascular age-related macular degeneration (AMD): a systematic review and network meta-analysis of direct comparative studies.2020Journal of Clinical Medicine
Efficacy and treatment burden of intravitreal aflibercept versus intravitreal ranibizumab treat-and-extend regimens at 2 years: network meta-analysis incorporating individual patient data meta-regression and matching-adjusted indirect comparison.2020Advances in Therapy
Comparative efficacy and safety of anti-vascular endothelial growth factor regimens for neovascular age-related macular degeneration: systematic review and Bayesian network meta-analysis.2020Therapeutic Advances in Chronic Disease
Intravitreal steroids for macular edema in diabetes.2020Cochrane Database of Systematic Reviews
Managing diabetic macular edema in clinical practice: systematic review and meta-analysis of current strategies and treatment options.2020Clinical Ophthalmology
Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.2020Cochrane Database of Systematic Reviews
Impact of intravitreal ranibizumab therapy on vision outcomes in diabetic macular edema patients: a meta-analysis.2020Ophthalmologica
Comparison of intravitreal bevacizumab and ranibizumab used for myopic choroidal neovascularization: a PRISMA-compliant systematic review and meta-analysis of randomized controlled trials.2019Medicine
Intravitreal corticosteroid implant vs intravitreal ranibizumab for the treatment of macular edema: a meta-analysis of randomized controlled trials.2019Drug, Design, Development and Therapy
Assessment report: Lucentis.2019European Medicines Agency
Effect of intravitreal anti-vascular growth factor agents with or without macular photocoagulation on diabetic macular edema: a systematic review and meta-analysis.2019Diabetes Therapy
Comparison of conbercept and ranibizumab for the treatment efficacy of diabetic macular edema: a meta-analysis and systematic review.2019International Journal of Ophthalmology
Current outcomes of anti-VEGF therapy in the treatment of macular oedema secondary to branch retinal vein occlusions: a meta-analysis.2019Ophthalmologica
A systematic review and meta-analysis of clinical outcomes of intravitreal anti-VEGF agent treatment immediately after cataract surgery for patients with diabetic retinopathy.2019Journal of Ophthalmology
Efficacy of ranibizumab for the treatment of diabetic retinopathy: a protocol for systematic review of randomized controlled trial.2019Medicine

Clinical Practice Guidelines